- Market Capitalization, $K 88,657
- Shares Outstanding, K 11,499
- Annual Sales, $ 0 K
- Annual Income, $ -25,870 K
- 60-Month Beta 1.64
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 1.75
|Period||Period Low||Period High||Performance|
| || |
+0.20 (+2.74%)since 05/24/19
| || |
+0.24 (+3.31%)since 03/25/19
| || |
-2.01 (-21.16%)since 06/25/18
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative...
-- Sustained Slowing of DMD Disease Progression with Edasalonexent Reinforced by Long Term MoveDMD MRI Data --
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2019 financial results before the Nasdaq Global Market open on...
Top Ranked Momentum Stocks to Buy for April 12th
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TTM Technologies, Inc. (NASDAQ:TTMI),...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase...
Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
As of late, it has definitely been a great time to be an investor in Catabasis.
The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.
Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
The market is approaching overbought territory. Be watchful of a trend reversal.